An overdose of this medicine is unlikely, as each dosage is specifically made to contain a specific amount of medication, and is administered by a healthcare provider. However, it is always important to seek immediate medical attention if you or someone else may have overdosed on this or any other drug.
If you miss your sipuleucel-T dose, contact your healthcare provider as soon as possible. This medication has a short window for use before it expires. If you do not receive your dose before the expiration day and time, you will need to have another procedure to collect your white blood cells, so a new dose can be created for you.
How Does It Work?
Sipuleucel-T is thought to work by stimulating the body's own immune system to attack prostate cancer cells. This is done by removing white blood cells from the body and exposing them to an antigen (a molecule that stimulates an immune response) that is made up of two important parts -- a protein found in most prostate cancer cells and a protein that activates the immune system. The white blood cells attack the antigen and display pieces of it on their surface.
When the white blood cells are introduced back into the bloodstream, they present the antigen pieces to T cells (a type of white blood cell). The T cells are now activated. Because they have been introduced to the protein found in prostate cancer cells, they are now able to recognize and attack the cancer.
In clinical studies, sipuleucel-T was shown to increase survival time when given to men with metastatic, hormone refractory prostate cancer (prostate cancer that has spread beyond the prostate, and is no longer responsive to hormone therapy). In these studies, men given sipuleucel-T survived an average of four months longer than men given a placebo (an injection that did not contain the active ingredient).
PROVENGE Web site. Available at: http://www.provenge.com. Accessed July 13, 2011.
Food and Drug Administration Web site. Vaccines, Blood and Biologics, Approved Products. PROVENGE. Available at: http://www.fda.gov/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/ucm210012.htm. Accessed July 13, 2011.
Food and Drug Administration Web site. Vaccines, Blood and Biologics, Resources for Healthcare Providers. Available at: http://www.fda.gov/BiologicsBloodVaccines/ResourcesforYou/HealthcareProviders/default.htm. Access July 13, 2011.
Food and Drug Administration Web site. Vaccines, Blood and Biologics, Questions and Answers about PROVENGE. Available at: http://www.fda.gov/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/ucm210037.htm. Accessed July 13, 2011.
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind.
Site users seeking medical advice about their specific situation should consult with their own physician. Click